Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches

Prostate Cancer is the forth most common type of cancer. Prostate-specific membrane antigen (PSMA) is anchored in the cell membrane of prostate epithelial cells. PSMA is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer. Therefore it is an appropriate target...

Descripción completa

Detalles Bibliográficos
Autores principales: Awang, Zool Hilmi, Essler, Markus, Ahmadzadehfar, Hojjat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966863/
https://www.ncbi.nlm.nih.gov/pubmed/29792198
http://dx.doi.org/10.1186/s13014-018-1037-7
_version_ 1783325522974998528
author Awang, Zool Hilmi
Essler, Markus
Ahmadzadehfar, Hojjat
author_facet Awang, Zool Hilmi
Essler, Markus
Ahmadzadehfar, Hojjat
author_sort Awang, Zool Hilmi
collection PubMed
description Prostate Cancer is the forth most common type of cancer. Prostate-specific membrane antigen (PSMA) is anchored in the cell membrane of prostate epithelial cells. PSMA is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer. Therefore it is an appropriate target for diagnostic and therapy of prostate cancer and its metastases. This article discusses several articles on radionuclide treatments in prostate cancer and the results on PSMA therapy with either beta or alpha emitters as a salvage therapy.
format Online
Article
Text
id pubmed-5966863
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59668632018-05-24 Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches Awang, Zool Hilmi Essler, Markus Ahmadzadehfar, Hojjat Radiat Oncol Review Prostate Cancer is the forth most common type of cancer. Prostate-specific membrane antigen (PSMA) is anchored in the cell membrane of prostate epithelial cells. PSMA is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer. Therefore it is an appropriate target for diagnostic and therapy of prostate cancer and its metastases. This article discusses several articles on radionuclide treatments in prostate cancer and the results on PSMA therapy with either beta or alpha emitters as a salvage therapy. BioMed Central 2018-05-23 /pmc/articles/PMC5966863/ /pubmed/29792198 http://dx.doi.org/10.1186/s13014-018-1037-7 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Awang, Zool Hilmi
Essler, Markus
Ahmadzadehfar, Hojjat
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
title Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
title_full Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
title_fullStr Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
title_full_unstemmed Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
title_short Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
title_sort radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966863/
https://www.ncbi.nlm.nih.gov/pubmed/29792198
http://dx.doi.org/10.1186/s13014-018-1037-7
work_keys_str_mv AT awangzoolhilmi radioligandtherapyofmetastaticcastrationresistantprostatecancercurrentapproaches
AT esslermarkus radioligandtherapyofmetastaticcastrationresistantprostatecancercurrentapproaches
AT ahmadzadehfarhojjat radioligandtherapyofmetastaticcastrationresistantprostatecancercurrentapproaches

Ejemplares similares